CRDF Q1 2021 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000+5.9% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$5M-7558.3% margin

Net Income

-$5M-7193.1% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

-39.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$268,000

Balance Sheet

Total Assets

$130M

Total Liabilities

$5M

Stockholders' Equity

$125M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$68,000	+5.9%
Gross Profit	$72,000	$68,000	+5.9%
Operating Income	-$5M	-$4M	-32.0%
Net Income	-$5M	-$4M	-26.7%